Evidence map›Paper›PMID 42058446›Full record

ArticleLancet regional health. Americas2026

Assessment of fatal cardiovascular disease risk using data-driven diabetes subgroups and SCORE2-Diabetes: a prospective, observational, population-based analysis of adults with diabetes in Mexico City.

Jerónimo Perezalonso-Espinosa, Juan Pablo Díaz-Sánchez, Daniel Ramírez-García, Karime Berenice Carrillo-Herrera, Leslie Alitzel Cabrera-Quintana, Carlos A Fermín-Martínez, Martín Roberto Basile-Álvarez, Andrea Malagón-Liceaga, Jaime Berumen, Pablo Kuri-Morales and 6 more

Abstract read
In one paragraph

Article in Lancet regional health. Americas, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors.

Jerónimo Perezalonso-EspinosaResearch Division, Instituto Nacional de Geriatría, Mexico City, Mexico.
Juan Pablo Díaz-SánchezResearch Division, Instituto Nacional de Geriatría, Mexico City, Mexico.
Daniel Ramírez-GarcíaResearch Division, Instituto Nacional de Geriatría, Mexico City, Mexico.
Karime Berenice Carrillo-HerreraResearch Division, Instituto Nacional de Geriatría, Mexico City, Mexico.
Leslie Alitzel Cabrera-QuintanaResearch Division, Instituto Nacional de Geriatría, Mexico City, Mexico.
Carlos A Fermín-MartínezResearch Division, Instituto Nacional de Geriatría, Mexico City, Mexico.
Martín Roberto Basile-ÁlvarezResearch Division, Instituto Nacional de Geriatría, Mexico City, Mexico.
Andrea Malagón-LiceagaResearch Division, Instituto Nacional de Geriatría, Mexico City, Mexico.
Jaime BerumenExperimental Research Unit, Faculty of Medicine, National Autonomous University of Mexico, Mexico City, Mexico.
Pablo Kuri-MoralesExperimental Research Unit, Faculty of Medicine, National Autonomous University of Mexico, Mexico City, Mexico.
Roberto Tapia-ConyerExperimental Research Unit, Faculty of Medicine, National Autonomous University of Mexico, Mexico City, Mexico.
Jesus Alegre-DíazExperimental Research Unit, Faculty of Medicine, National Autonomous University of Mexico, Mexico City, Mexico.
Neftali Eduardo Antonio-VillaDepartments of Global Health and Population, Epidemiology, Harvard T.H. Chan School of Public Health, USA.
Goodarz DanaeiDepartments of Global Health and Population, Epidemiology, Harvard T.H. Chan School of Public Health, USA.
Jacqueline A SeiglieDiabetes Unit, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Omar Yaxmehen Bello-ChavollaResearch Division, Instituto Nacional de Geriatría, Mexico City, Mexico.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Cardiovascular disease (CVD) is a leading cause of diabetes-related mortality in Mexico. Although diabetes subgroups capture underlying disease heterogeneity, their association and utility for risk prediction for fatal CVD in Mexican adults remain unclear. Here, we aimed to assess the risk of fatal CVD risk and their complementary role for fatal CVD risk prediction across diabetes subgroups in Mexican adults. Methods: We included adults with diabetes from the Mexico City Prospective Study (MCPS). Participants were classified into mild obesity-related (MOD), severe insulin-deficient (SIDD), severe insulin-resistant (SIRD), and mild age-related (MARD) diabetes using a self-normalizing neural network algorithm. Fatal CVD was defined as death from ischemic heart disease or stroke (ICD-10 I20-I25, I60-I69). SCORE2-Diabetes was internally recalibrated for fatal CVD outcomes only for use within MCPS, as this does not represent a formal validation of the original composite endpoint. Cause-specific Cox proportional hazards and Fine & Gray competing risk regression models were used to estimate subgroup-specific risk, and sequential models evaluated the incremental predictive value of diabetes subgroups combined with SCORE2-Diabetes and traditional risk factors. Findings: We analyzed data from 24,943 adults living with diabetes (mean age 58 ± 12, 67% female, no ethnicity data available). Over a median follow-up of 19.3 years (IQR 12.7-20.6), 2218 fatal CVD events (8.9%) were recorded. SIDD was the most prevalent subgroup (50.0%), followed by SIRD (14.1%), MARD (17.7%), and MOD (18.3%). SIDD and MARD showed the highest adjusted risk of fatal CVD (HR 1.58 [95% CI 1.38-1.81] and 1.35 [1.13-1.60]), whereas MOD and SIRD had lower risk, even when considering competing causes of non-CVD deaths. Recalibrated SCORE2-Diabetes demonstrated adequate discrimination overall (c-statistic 0.748, 95% CI 0.734-0.762) and for most diabetes subgroups but underperformed in MARD, with internal recalibration for fatal CVD outcomes improving risk assessment. The combination of diabetes subgroups and SCORE2-Diabetes modestly improved prediction for fatal CVD outcomes. Interpretation: Diabetes subgroups show heterogeneity in fatal CVD risk in Mexican adults. SIDD and MARD identify high-risk individuals and integration subgroup classification with SCORE2-Diabetes is complementary for fatal CVD risk prediction. Funding: This research was supported by a grant provided by the Bernard Lown Scholars in Cardiovascular Health Program grant number BLSCHP-2403.

Indexed as

Cardiovascular diseaseDiabetes mellitusDiabetes subgroupsMexican populationSCORE2-Diabetes

Identifiers

PMID42058446
PMCPMC13123577

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.